A New Big-Data Paradigm for Target Identification and Drug Discovery
暂无分享,去创建一个
Neel Madhukar | Paraskevi Giannakakou | Kaitlyn Gayvert | Olivier Elemento | Kaitlyn M. Gayvert | Prashant K. Khade | Neel S. Madhukar | Martin Stogniew | Giuseppe Galletti | O. Elemento | P. Giannakakou | Linda Huang | Joshua E. Allen | M. Stogniew | G. Galletti | J. Allen | Linda Huang | J. Allen
[1] Justin Lamb,et al. The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.
[2] Avi Ma'ayan,et al. Lean Big Data integration in systems biology and systems pharmacology. , 2014, Trends in pharmacological sciences.
[3] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[4] E. Messaris,et al. Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects , 2013, Science Translational Medicine.
[5] M. Jordan,et al. Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.
[6] Louiqa Raschid,et al. Ieee/acm Transactions on Computational Biology and Bioinformatics 1 Network-based Drug-target Interaction Prediction with Probabilistic Soft Logic , 2022 .
[7] David S. Wishart,et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..
[8] Lin He,et al. Prediction of Drug-Target Interactions for Drug Repositioning Only Based on Genomic Expression Similarity , 2013, PLoS Comput. Biol..
[9] Chartchalerm Isarankura-Na-Ayudhya,et al. Advances in computational methods to predict the biological activity of compounds , 2010, Expert opinion on drug discovery.
[10] H. Hsieh,et al. Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent. , 2003, Biochemical pharmacology.
[11] A. Frantz,et al. Dopamine antagonism by thioridazine in schizophrenia. , 1975, Biological psychiatry.
[12] D. Butina,et al. Predicting ADME properties in silico: methods and models. , 2002, Drug discovery today.
[13] F. Monsma,et al. Characterizing Cannabinoid CB 2 Receptor Ligands Using DiscoveRx PathHunter™ β-Arrestin Assay , 2009, Journal of biomolecular screening.
[14] N. Lawrence,et al. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle , 1998, Medicinal research reviews.
[15] Avi Ma'ayan,et al. Drug-induced adverse events prediction with the LINCS L1000 data , 2016, Bioinform..
[16] M. Jordan,et al. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. , 1998, Current opinion in cell biology.
[17] R. Venkataraghavan,et al. Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..
[18] R. Davis,et al. ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition , 2014 .
[19] Yoshihiro Yamanishi,et al. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..
[20] Hiroyuki Ogata,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..
[21] Thomas Lengauer,et al. A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.
[22] C. Marsden,et al. Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias. , 1978, British medical journal.
[23] John C. Dearden,et al. In silico prediction of drug toxicity , 2003, J. Comput. Aided Mol. Des..
[24] Yoshihiro Yamanishi,et al. Predicting target proteins for drug candidate compounds based on drug-induced gene expression data in a chemical structure-independent manner , 2015, BMC Medical Genomics.
[25] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[26] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[27] Corey Nislow,et al. Recent advances and method development for drug target identification. , 2010, Trends in pharmacological sciences.
[28] C. Clarke,et al. Beta-blocker therapy for tremor in Parkinson's disease. , 2003, The Cochrane database of systematic reviews.
[29] Yongdong Zhang,et al. Drug-target interaction prediction: databases, web servers and computational models , 2016, Briefings Bioinform..
[30] A. Borsodi,et al. Microtubule dissassembly increases the number of opioid receptor binding sites in rat cerebrum membranes , 1986, Neuropeptides.
[31] Ru Zhang,et al. Tools for GPCR drug discovery , 2012, Acta Pharmacologica Sinica.
[32] Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area , 2014, European Journal of Clinical Pharmacology.
[33] Hua Xu,et al. Identifying Plausible Adverse Drug Reactions Using Knowledge Extracted from the Literature , 2014, AMIA.
[34] Eiman Mukhtar,et al. Targeting Microtubules by Natural Agents for Cancer Therapy , 2014, Molecular Cancer Therapeutics.
[35] J. Weigelt. The case for open‐access chemical biology , 2009, EMBO reports.
[36] W. El-Deiry,et al. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity , 2014, Oncotarget.
[37] Xiaomin Luo,et al. TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..
[38] Bin Chen,et al. PubChem BioAssays as a data source for predictive models. , 2010, Journal of molecular graphics & modelling.
[39] Igor Jurisica,et al. Prioritizing Therapeutics for Lung Cancer: An Integrative Meta-analysis of Cancer Gene Signatures and Chemogenomic Data , 2015, PLoS Comput. Biol..
[40] K. Nicolaou,et al. Synthesis of epothilones A and B in solid and solution phase , 1997, Nature.
[41] Roded Sharan,et al. Combining Drug and Gene Similarity Measures for Drug-Target Elucidation , 2011, J. Comput. Biol..
[42] Pedro Cuatrecasas,et al. Drug discovery in jeopardy. , 2006, The Journal of clinical investigation.
[43] Theonie Anastassiadis,et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.
[44] J. Gerlach,et al. Oxiperomide in tardive dyskinesia. , 1980, Journal of neurology, neurosurgery, and psychiatry.
[45] P. Marchetti,et al. Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study , 2014, Journal of Cancer.
[46] T. Fojo,et al. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. , 2000, Journal of the National Cancer Institute.
[47] K. Nicolaou,et al. Design, synthesis, and biological properties of highly potent epothilone B analogues. , 2003, Angewandte Chemie.
[48] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[49] A. L. Risinger,et al. Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent , 2015, Clinical Cancer Research.
[50] P. Kunapuli,et al. A combination of ultrahigh throughput PathHunter and cytokine secretion assays to identify glucocorticoid receptor agonists. , 2009, Analytical biochemistry.
[51] David S. Wishart,et al. DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..
[52] S. Bryant,et al. PubChem as a public resource for drug discovery. , 2010, Drug discovery today.
[53] E. Nogales,et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[54] T. Fojo,et al. Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* , 1997, The Journal of Biological Chemistry.
[55] D. Cooper,et al. Adverse effects of antiretroviral therapy , 2000, The Lancet.